Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + nab-P-SOX for Neoadjuvant Gastric/GEJ Cancer
NCT07867392Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Started Feb 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07867392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867392.